← Human Trials & Peer-Reviewed Studies
Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response
Plain-language guide to PMID 28073779 (2017): double-blind randomized controlled trial study of GIP (Gastric Inhibitory Polypeptide).
Key Facts
- PMID
- 28073779
- Journal
- American journal of physiology. Endocrinology and metabolism
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Thondam SK et al. (9 authors)
- DOI
- 10.1152/ajpendo.00347.2016
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at GIP (Gastric Inhibitory Polypeptide).
Glucose-dependent insulinotropic polypeptide (GIP) beyond its insulinotropic effects may regulate postprandial lipid metabolism.
Whereas the insulinotropic action of GIP is known to be impaired in type 2 diabetes mellitus (T2DM), its adipogenic effect is unknown.
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, men only.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind GIP (Gastric Inhibitory Polypeptide) study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the GIP (Gastric Inhibitory Polypeptide) group a baseline to be compared against.
In the crossover set-up each of the participants took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.
What Was Measured
The subject headings attached to it are Adipocytes, Adipogenesis, Blood Glucose, Case-Control Studies, Diabetes Mellitus, Type 2, Esterification and Fatty Acids, Nonesterified.
Author keywords: adipose tissue, glucose-dependent insulinotropic polypeptide, lipid metabolism, nonesterified fatty acids and type 2 diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide).
The publication is from 2017 (American journal of physiology. Endocrinology and metabolism), a journal based in United States.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.